Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma.

The Cu/Zn ratio could serve as a useful predictive marker for survival in cases of HCC. MT levels increased in HCC patients receiving lenvatinib therapy, and maybe a predictor of reduced survival.